Trial Profile
Orlistat for the Treatment of Type I Hyperlipoproteinemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Orlistat (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Therapeutic Use
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 23 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 08 Sep 2021 Planned End Date changed from 31 Jul 2021 to 31 Dec 2021.